TriangleNCT05198934 · MORE INFO
Limitations, agreements, and source contact
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- certain Agreement
- other Details
- The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
- pi Sponsor Employee
- false
- restriction Type
- OTHER
- restrictive Agreement
- true
- point Of Contact
- medinfo@amgen.com
- organization
- Amgen Inc.
- phone
- 866-572-6436
- title
- Study Director
Complete source fields
- certain Agreement
- other Details
- The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
- pi Sponsor Employee
- false
- restriction Type
- OTHER
- restrictive Agreement
- true
- point Of Contact
- medinfo@amgen.com
- organization
- Amgen Inc.
- phone
- 866-572-6436
- title
- Study Director
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Independent clinical review pending · Not medical advice